secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001549595-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL
--------------------------------------------------------------------------------

- Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.
- Cash and marketable securities at $373.0M on Nov 30, 2022, down from $432.9M at Nov 30, 2021; collaboration revenue $38.6M.
- NX-2127 BTK degrader achieved clinical responses in heavily pretreated CLL patients with BTK inhibitor resistance mutations.
- Initial PK/PD data for NX-5948 showed rapid, sustained BTK degradation; FDA clearance for US trial expansion received Dec 2022.
- Nurix expects to present additional clinical data for NX-2127, NX-5948, and NX-1607 in 2H 2023; partnered 10 discovery programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/0001549595-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000020/nrix-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer